{
    "clinical_study": {
        "@rank": "102446", 
        "arm_group": {
            "arm_group_label": "isavuconazole and sirolimus", 
            "arm_group_type": "Experimental", 
            "description": "Single dose of sirolimus on Days 1 and 26, isavuconazole 3 times a day (TID) for 2 days (Days 22 to 23) followed by once a day (QD) for 11 days"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to assess the effect of multiple doses of isavuconazole on the\n      pharmacokinetics (PK) of sirolimus after single dose administration."
        }, 
        "brief_title": "A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus in Healthy Subjects", 
        "completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Subjects", 
            "Pharmacokinetics of Isavuconazole", 
            "Pharmacokinetics of Sirolimus"
        ], 
        "detailed_description": {
            "textblock": "Subjects will receive a single dose of sirolimus on Day 1 followed by a 21 day wash-out\n      period (time from sirolimus dosing to isavuconazole dosing). On Days 22 and 23,\n      isavuconazole will be dosed three times daily (TID). On Days 24 through 34, isavuconazole\n      will be administered once daily (QD). All subjects will be administered a single dose of\n      sirolimus on Day 26."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject has a body weight of at least 45 kg and has a body mass index (BMI) of 18\n             to 32 kg/m2, inclusive\n\n          -  Results for aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must\n             be within the normal range\n\n          -  The female subject agrees to sexual abstinence, or is surgically sterile,\n             postmenopausal (defined as at least 2 years without menses), or using a medically\n             acceptable double barrier method (e.g. spermicide and diaphragm, or spermicide and\n             condom) to prevent pregnancy and agrees to continue using this method from Screening\n             until 3 weeks after the follow-up visit at the end of the study; and is not lactating\n             or pregnant as documented by negative pregnancy tests\n\n          -  The male subject agrees to sexual abstinence, is surgically sterile, or is using a\n             medically acceptable method to prevent pregnancy and agrees to continue using this\n             method from Screening until 3 weeks after the follow-up visit at the end of the study\n\n        Exclusion Criteria:\n\n          -  The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac\n             arrhythmia or torsade de pointes, structural heart disease, or family history of Long\n             QT syndrome (suggested by sudden death of a close relative at a young age due to\n             possible or probable cardiac causes)\n\n          -  The subject has a history of tuberculosis or exposure to anyone known or suspected to\n             have tuberculosis or any illness that, in the opinion of the investigator, might\n             confound the results of the study or pose additional risk in administering study drug\n             to the subject\n\n          -  The subject has a positive result for hepatitis C antibodies, hepatitis B surface\n             antigen, or QuantiFERON\u00ae-TB Gold test or is known to be positive for human\n             immunodeficiency virus (HIV).\n\n          -  The subject has a known or suspected allergy to any of the components of the trial\n             products including prednisone or the azole class of compounds, or a history of\n             multiple and/or severe allergies to drugs or foods, or a history of severe\n             anaphylactic reactions\n\n          -  The subject is a smoker (any use of tobacco or nicotine containing products) within 6\n             months prior to Screening\n\n          -  The subject has had treatment with prescription drugs or complementary and\n             alternative medicines within 14 days prior to Day -1, or over-the-counter medications\n             within 1 week prior to Day -1, with the exception of acetaminophen up to 2 g/day\n\n          -  The subject has a recent history (within the last 2 years) of drug or alcohol abuse,\n             or a positive drug and/or alcohol screen"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01809860", 
            "org_study_id": "9766-CL-0020"
        }, 
        "intervention": [
            {
                "arm_group_label": "isavuconazole and sirolimus", 
                "description": "Oral", 
                "intervention_name": "isavuconazole", 
                "intervention_type": "Drug", 
                "other_name": "BAL8557"
            }, 
            {
                "arm_group_label": "isavuconazole and sirolimus", 
                "description": "Oral", 
                "intervention_name": "sirolimus", 
                "intervention_type": "Drug", 
                "other_name": "Rapamune"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "isavuconazole", 
            "sirolimus", 
            "BAL8557", 
            "Healthy Volunteers"
        ], 
        "lastchanged_date": "March 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75247"
                }, 
                "name": "Covance"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus: A Phase 1, Open-Label, Sequential Study in Healthy Adult Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Global Development, Inc.", 
            "last_name": "Senior Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the concentration-time curve (AUC) from time 0 extrapolated to infinity (AUCinf)", 
                "measure": "Pharmacokinetics (PK) of sirolimus in whole blood:  AUCinf", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 26 at predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours postdose"
            }, 
            {
                "description": "AUC from the time of dosing to the last quantifiable concentration (AUClast)", 
                "measure": "PK of sirolimus in whole blood:  AUClast", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 26 at predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours postdose"
            }, 
            {
                "description": "Maximum concentration (Cmax)", 
                "measure": "PK of sirolimus in whole blood:  Cmax", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 26 at predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours postdose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01809860"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time to attain Cmax (tmax), apparent volume of distribution (Vz/F), apparent body clearance after oral dosing (CL/F), and apparent terminal elimination half-life (t1/2)", 
                "measure": "Composite of PK variables of sirolimus in whole blood:  tmax, Vz/F, CL/F, and t 1/2", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 26 at predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours postdose"
            }, 
            {
                "description": "trough concentration (Ctrough)", 
                "measure": "PK variable of isavuconazole in plasma:  Ctrough", 
                "safety_issue": "No", 
                "time_frame": "Day 24 and Days 28 through 35 predose"
            }, 
            {
                "description": "AUC during the time interval between consecutive dosing (AUCtau)", 
                "measure": "Composite of PK variables of isavuconazole in plasma: AUCtau, Cmax, and tmax", 
                "safety_issue": "No", 
                "time_frame": "Day 25, predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 16 hours postdose; Day 26 predose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24 and 36 hours postdose"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Basilea Pharmaceutica International Ltd", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Global Development, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}